31 Oct 2022 , 06:48 AM
Result date: 1st November, 2022
Recommendation: Add
Target price: Rs1,040
(Source: IIFL Research)
Sun Pharmaceutical Industries (Sun Pharma) could post ~17% growth in revenue over the year-ago quarter amid continued traction in its Specialty segment and domestic formulation business.
Sun Pharma’s EBITDA could grow 6.1% over the year-ago quarter, reflecting the strength in topline.
Consequently, the company’s Profit After Tax (PAT) could grow 4.2% over the year-ago quarter.
Important management insights to watch out for:
· Outlook on margins
· Update on new launches
Rs. Million | September 2022 estimates | QoQ change | YoY change |
Revenue | 111,933 | 4.6% | 16.7% |
EBITDA | 30,042 | 7.2% | 6.1% |
Profit After Tax | 21,725 | 5.5% | 4.2% |
Source: Brokerage Reports
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.